Latest Alpha-synuclein Stories
KIRKLAND, Wash., Feb 26 /PRNewswire/ -- ProteoTech Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Disease Research. In collaboration with Avid Radiopharmaceuticals Inc.
A novel approach to analyzing cellular data is yielding new understanding of Parkinson's disease's destructive pathways.
NEW YORK, Feb. 18 /PRNewswire-USNewswire/ -- The Michael J.
Neurologists have observed for decades that Lewy bodies, clumps of aggregated proteins inside cells, appear in the brains of patients with Parkinson's disease and other neurodegenerative diseases.
VIENNA, Austria, December 11 /PRNewswire/ -- AFFiRiS has started pre-clinical development of a Parkinson's vaccine. The vaccine, known as PD01, can be used to target a specific protein that is closely associated with the causes of this degenerative neurological disease.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has published new research with collaborators at Mayo Clinic in the journal Molecular Neurodegeneration.
By Mrak, Robert E Griffin, W Sue T Abstract Cortical Lewy body disease as a cause of dementia has been recognized for more than 40 years.
Researchers at the University of California, San Diego (UCSD) School of Medicine have developed a series of transgenic mouse models of multiple system atrophy, a progressive, fatal neurological disorder. The work is reported in the November 16 issue of the Journal of Neuroscience by Eliezer Masliah, M.D., Professor of Neuroscience and Pathology at UCSD and Cliff Shults, M.D. Professor of Neuroscience at UCSD and Neurologist at the VA San Diego Healthcare System.
Researchers at UT Southwestern Medical Center have discovered that a protein associated with causing neurodegenerative conditions may, when appearing in normal amounts, actually protect against neurodegeneration.
- The governor of a province or people.